Lead R&D Scientist to Present Breakthrough Multi-Cancer Early Detection Research Findings at Prestigious ASCO Annual Meeting 2024 in Chicago

  • News

As a significant development for the MCED community, Dr. Le Son Tran, the lead R&D scientist from Medical Genetics Institute Ho Chi Minh City and Gene Solutions is set to present breakthrough findings at the upcoming prestigious oncology conference this weekend.

The landscape of MCED tests based on detecting methylation changes in cfDNA has evolved but current solutions still exhibit low sensitivity for detecting certain cancers (e.g., breast cancer) and early-stage tumors owing to low amount and high heterogeneity of ctDNA. To improve the detection sensitivity of ctDNA, MCED screening methods tend to use high-depth sequencing, making it economically impractical for population-wide screening. To address these limitations, the team at Medical Genetics Institute Ho Chi Minh City and Gene Solutions developed a novel approach – Screening for the Presence Of Tumor by Methylation And Size (SPOT-MAS), which offers a comprehensive analysis through the integration of methylation, fragment length profile, DNA copy number aberration and end motif in a single library reaction. It was designed to simultaneously detect five common types of cancer, including liver, breast, colorectal, gastric, and lung cancer, and predict the tissue origin of cancer signal1. The performance and findings from a multi-centre prospective study support the utility of SPOT-MAS as a multi-cancer blood test for early cancer detection, particularly in low- and middle-income countries lacking nationwide cancer screening programs2.

Innovative Research: The scientist will discuss innovative approaches to ctDNA analysis using SPOT-MAS for Multi-Cancer Early Detection of asymptomatic individuals, potentially revolutionizing cancer preventive care.

Rigorous Analytical and Clinical Validation: The team undertook the K-DETEK multi-centre prospective study to validate the diagnostic performance of SPOT-MAS, recruiting 10,027 asymptomatic individuals aged 40 years or older.

Future of Oncology: The strong performance of SPOT-MAS in the K-DETEK study underpins the potential to shape the future direction of oncology research and treatment.

The research team welcomes collaborative opportunities and anticipates our participation at ASCO Annual Meeting will provide a platform for collaboration among top oncology professionals.

The conference will run from May 31 to June 4, at McCormick Place, Chicago USA and is also available online. It is an opportunity not to be missed for anyone interested in the forefront of cancer research. For more information and to register for the event, please visit https://conferences.asco.org/am/attend.

Workflow of SPOT-MAS (screening for the presence of tumor by methylation and size) assay for multi-cancer detection and localization1.

Overview of analytical and clinical validation2

 

  1. Van Thien Chi Nguyen, et al (2023) Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization eLife 12:RP89083 https://doi.org/10.7554/eLife.89083.3
  2. Luu Hong Dang Nguyen et al, Analytical and clinical validation of a circulating tumor DNA-based assay for multi-cancer early detection. medRxiv 12.22.23300420; doi: https://doi.org/10.1101/2023.12.22.23300420

 

Facebook
Twitter
Pinterest

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More